Free Trial

Elutia (ELUT) Competitors

Elutia logo
$1.92 +0.02 (+1.05%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.92 +0.01 (+0.26%)
As of 07/25/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELUT vs. TNXP, FHTX, CADL, AURA, ABEO, PRTA, ATXS, ALT, AMRN, and PVLA

Should you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), Candel Therapeutics (CADL), Aura Biosciences (AURA), Abeona Therapeutics (ABEO), Prothena (PRTA), Astria Therapeutics (ATXS), Altimmune (ALT), Amarin (AMRN), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry.

Elutia vs. Its Competitors

Elutia (NASDAQ:ELUT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Elutia presently has a consensus price target of $8.00, indicating a potential upside of 316.67%. Tonix Pharmaceuticals has a consensus price target of $70.00, indicating a potential upside of 40.79%. Given Elutia's higher possible upside, analysts clearly believe Elutia is more favorable than Tonix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elutia
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tonix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

74.0% of Elutia shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Elutia has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.

In the previous week, Elutia and Elutia both had 2 articles in the media. Elutia's average media sentiment score of 1.77 beat Tonix Pharmaceuticals' score of 0.62 indicating that Elutia is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elutia
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Tonix Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Elutia has higher revenue and earnings than Tonix Pharmaceuticals. Elutia is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elutia$24.38M3.24-$53.95M-$1.93-0.99
Tonix Pharmaceuticals$10.09M36.27-$130.04M-$1.96 thousand-0.03

Elutia has a net margin of -168.23% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Elutia's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Elutia-168.23% N/A -96.70%
Tonix Pharmaceuticals -1,313.87%-120.96%-101.28%

Summary

Elutia beats Tonix Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELUT vs. The Competition

MetricElutiaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$78.12M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-0.9921.1828.1020.05
Price / Sales3.24286.17429.0189.19
Price / CashN/A42.7636.2258.56
Price / Book-1.478.378.665.87
Net Income-$53.95M-$55.19M$3.25B$258.55M
7 Day Performance-9.43%5.88%4.22%3.73%
1 Month Performance3.78%17.33%10.51%11.75%
1 Year Performance-49.21%4.42%34.40%18.03%

Elutia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELUT
Elutia
3.8021 of 5 stars
$1.92
+1.1%
$8.00
+316.7%
-48.8%$78.12M$24.38M-0.99180Positive News
Upcoming Earnings
TNXP
Tonix Pharmaceuticals
2.6031 of 5 stars
$45.10
-3.9%
$70.00
+55.2%
-14.2%$345.13M$10.09M0.0050
FHTX
Foghorn Therapeutics
2.142 of 5 stars
$6.10
-0.5%
$12.13
+98.8%
-5.1%$341.70M$22.60M-4.49120News Coverage
CADL
Candel Therapeutics
2.0909 of 5 stars
$6.57
-2.5%
$22.00
+234.9%
+7.8%$337.69M$120K-4.9060
AURA
Aura Biosciences
2.4353 of 5 stars
$6.77
+0.9%
$22.00
+225.0%
-29.6%$337.30MN/A-3.5650News Coverage
Positive News
ABEO
Abeona Therapeutics
3.7543 of 5 stars
$6.75
+2.4%
$19.25
+185.2%
+29.8%$337.12M$3.50M-5.3190
PRTA
Prothena
3.7494 of 5 stars
$6.29
+0.5%
$31.50
+400.8%
-73.1%$336.96M$135.16M-3.02130
ATXS
Astria Therapeutics
1.9173 of 5 stars
$6.26
+4.9%
$30.00
+379.2%
-44.4%$336.91MN/A-3.3530
ALT
Altimmune
2.0894 of 5 stars
$4.05
-0.7%
$18.20
+349.4%
-39.0%$330.92M$20K-3.2150
AMRN
Amarin
0.2424 of 5 stars
$15.55
-1.7%
$12.00
-22.8%
-2.7%$327.58M$228.61M-4.27360Positive News
Upcoming Earnings
PVLA
Palvella Therapeutics
1.4301 of 5 stars
$31.00
+5.0%
$47.50
+53.2%
N/A$326.25M$42.81M-2.56N/A

Related Companies and Tools


This page (NASDAQ:ELUT) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners